We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

RNAZ TransCode Therapeutics Inc

0.001 (0.46%)
Dec 04 2023 - Closed
Delayed by 15 minutes


Draw Mode:

Volume 1,989,994
Bid Price 0.221
Ask Price 0.2339
News (2)
Day High 0.24


52 Week Range


Day Low 0.223
Share Name Share Symbol Market Stock Type
TransCode Therapeutics Inc RNAZ NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
0.001 0.46% 0.22 18:59:43
Open Price Low Price High Price Close Price Previous Close
0.23 0.223 0.24 0.228 0.219
Trades Shares Traded VWAP Financial Volume Average Volume 52 Week Range
2,949 1,989,994 US$ 0.233147 US$ 463,961 - 0.1494 - 23.40
Last Trade Type Quantity Price Currency
18:58:06 formt 1,500 US$ 0.22 USD

TransCode Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
4.62M 20.10M - 0 -17.57M -0.87 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

TransCode Therapeutics News

Date Time Source News Article
12/04/202316:07Edgar (US Regulatory)Form 8-K - Current report
12/04/202315:10GlobeNewswire Inc.TransCode Therapeutics Announces Closing of $1.2 Million..
12/01/202316:23Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]
11/30/202313:53GlobeNewswire Inc.TransCode Therapeutics Announces $1.2 Million Registered..
11/14/202315:40Edgar (US Regulatory)Form 8-K - Current report
11/14/202315:30GlobeNewswire Inc.TransCode Therapeutics Reports Third Quarter 2023 Results;..
11/09/202315:13Edgar (US Regulatory)Form 8-K - Current report
10/31/202321:20AllPennyStocks.comBiotech Shares Bid Up Following Public Offering Cancellation
10/30/202315:33GlobeNewswire Inc.TransCode Therapeutics Withdraws Public Offering
10/27/202315:06Edgar (US Regulatory)Form 8-K - Current report
10/27/202307:00GlobeNewswire Inc.Nasdaq Panel Grants TransCode Therapeutics Extension for..
10/26/202315:29Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No RNAZ Message Board. Create One! See More Posts on RNAZ Message Board See More Message Board Posts

Historical RNAZ Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.230.46660.21050.24354747,748,716-0.01-4.35%
1 Month0.3640.48560.14940.26273563,117,405-0.144-39.56%
3 Months1.033.200.14940.89618457,511,455-0.81-78.64%
6 Months3.954.160.14940.9617163,646,428-3.73-94.43%
1 Year8.54223.400.14946.382,999,204-8.32-97.42%
3 Years120.00140.000.149427.551,822,492-119.78-99.82%
5 Years120.00140.000.149427.551,822,492-119.78-99.82%

TransCode Therapeutics Description

TransCode Therapeutics Inc is an RNA oncology company. It is created to defeat the cancer through the intelligent design and effective delivery of RNA therapeutics. The company's lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has the potential to produce regression without recurrence in a range of cancers, including breast, pancreatic, ovarian and colon cancer, glioblastomas and others.

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |